Business Wire

Arthur D. Little: New Report Offers a Blueprint for Overcoming Bottlenecks and Unlocking the Full Potential of Digitalisation in the Chemical Industry

19.4.2023 10:51:00 EEST | Business Wire | Press release

Share

Digitalisation has the power to transform the European chemical industry, revolutionising the sector's solutions and enabling a circular, more sustainable economy in line with the EU Green Deal objectives. This exciting potential is highlighted in a new report from Arthur D. Little and Cefic, the European Chemical Industry Council, which details how technologies like artificial intelligence, big data, Internet of Things, digital twins, robotics, virtual/augmented reality, and blockchain can accelerate the industry's transformation.

The study titled "Digital Technologies for Sustainability in the European Chemical Industry", is the first ever attempt to outline how these technologies are used in the chemical sector and how they can be scaled up to make the chemical industry’s processes and products more sustainable .

Dr. Daniel Witthaut, Executive Director for Innovation at Cefic, emphasises that while the EU chemical industry has already implemented digitalisation in various applications, there is still much more that can be done:

“Digitalisation in the chemical industry is not new with multiple players already applying digital technologies in their fields. However, enormous opportunities exist for the industry to reach their sustainability goals faster through the application of the latest digital technologies – a journey that is just beginning for most players. And this is where we also need to work more closely with EU institutions to remove existing bottlenecks, improve data sharing and create a larger pool of homegrown talent to implement all these new technologies”.

According to the research, digital technologies can make the greatest contribution in five priority areas in both large and small companies in the EU: (1) process design and production for climate and circularity objectives, (2) sustainability assessment, (3) enabling materials and chemicals circularity through tracking and tracing, (4) sustainable product design, and (5) safe and efficient logistics and distribution.

Dr. Michaël Kolk, Managing Partner at ADL, adds: “Chemical companies in Europe are not only working on their own sustainability objectives, but also providing solutions that serve as enablers for many downstream industries to reach their own. The picture is complex, but we believe that collaboration via greater digitalisation is the way forward.”

The report also highlights a number of challenges that must be addressed to fully realise the potential of digital technologies. These include technological challenges such as data availability, interoperability, standardisation and cybersecurity as well as reluctance among companies to share data, financial costs, organisational issues, and a shortage of digital skills in the workforce. Greater collaboration between EU institutions and the chemical industry will be needed to address some of these bottlenecks.

The report is available for download here: https://tinyurl.com/2s4bztsb

END

About the report

Arthur D. Little and the European Chemical Industry Council (Cefic) joined forces to prepare this report, which summarises the views of digital technology experts from within and outside the chemical industry.

Recommendations from this report are based on the result of 15 individual interviews with senior digital and sustainability experts (e.g., chief digital officers or chief sustainability officers) as well as a survey of more than 70 experts from 50 companies that are broad representatives of the chemical industry in terms of type of business, size, and region.

To add cross-industry perspectives, the study also took into account input from more than 10 globally recognised digital technology experts outside the chemical industry.

About Cefic

Cefic, the European Chemical Industry Council, founded in 1972, is the voice of large, medium and small chemical companies across Europe, which provide 1.2 million jobs and account for approximately about 15% of world chemicals production.

About Arthur D. Little

Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.

Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.

For further information, please visit www.adlittle.com or www.adl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Marina Mendes
Cefic
+32 499239522
mam@cefic.be

Media contact: Sue Glanville
Catalyst Comms
+44 7715 817589
Glanville.sue@adlittle.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye